| Abstract |
[Abstract] Objective To explore the clinical efficacy of fluoxetine combined with brain function therapy in the treatment of depression. Methods The clinical data of 80 cases of patients with depression in our hospital from April 2015 to April 2017 were statistically analyzed, these patients were divided with fluoxetine combined with brain function therapy apparatus treatment group (combined treatment group, n=40) and single fluoxetine treatment group (single treatment group, n=40) two groups according to the treatment methods, the HAMD scores, SSS scores, BI indexes, clinical efficacy, sleep and insight improvement situations, treatment compliance and incidences of adverse reactions of the two groups were statistically analyzed. Results The HAMD score, SSS score of the combined treatment group were significantly lower (P<0.05), the BI index was significantly higher (P<0.05), the total treatment efficiency 90.0% (36/40) was significantly higher than the single treatment group 75.0% (30/40) (P<0.05), the sleep improvement rate, insight improvement rate, treatment compliance 92.5% (37/40), 95.0% (38/40), 90.0% (36/40) were significantly higher than the single treatment group 82.5% (33/40), 77.5% (31/40), 82.5% (33/40) (P<0.05), but the difference of adverse reactions occurred rates between the two groups was not significant 10.0% (4/40), 7.5% (3/40) (P>0.05). Conclusion The clinical efficacy of fluoxetine combined with brain function therapy in the treatment of depression is more significant than single fluoxetine treatment.
|